| Prev Close | 4.41 |
| Open | 4.40 |
| Day Low/High | 4.18 / 4.46 |
| 52 Wk Low/High | 4.19 / 9.11 |
| Volume | 1.82M |
| Avg Volume | 595.10K |
Corbus Pharmaceuticals Holdings Inc. (CRBP)
4.36
0.05
1.13
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 64.67M |
| Market Cap | 296.53M |
| EPS | -1.00 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
There Is Generally Good Action on My Screens Today
The price action is quite good.
Trading Notes for Select Stocks
Here's my take on a list of stocks I've been watching.
Tuesday's Rally Was Driven Mostly by Technical Conditions
Market players didn't see it coming and that is what helped it gain so much strength.
It's a Stock Picker's Delight Right Now
With cash levels high, those players who are not well-positioned for upside action are scrambling to put money to work and are helping to propel prices higher.
Texas Instruments Exemplifies Drag of Lackluster Earnings on Market
There have been some solid earnings reports, but they haven't provided a boost to the broader market.
Square Continues to See Extreme Pressure
If you are interested in Square longer term be patient and wait for the drama to end.
Can Corbus Pharmaceuticals Hold Its Gains?
CRBP rocketed 53% Thursday on news of a deal with Jenrin Discovery to study 600 of their cannabinoid compounds.
Trading Hot Sectors Like Cannabis Regardless of Valuations
These speculative frenzies all have a number of things in common.
Cannabis Frenzy Continues With New Age Beverages and Corbus Pharmaceuticals
Aggressive traders are beating the bushes looking for the next big mover.
Keep Buying Pot Stocks; Weed Isn't Going Away
Selloffs like the one in marijuana stocks present entry points, if this is your cup of tea.
California Dreamin': Searching for a 'Pot' of Gold Through Marijuana Stocks
On Monday, recreational use of marijuana will be legal in California, so let's visit 3 weed stocks.
Biotechs Remain the Best Place For Stock Picking
Biotech companies show more energy than the rest of the market Monday.
A Few Names on my Radar on This Softness
The indices may test intraday lows, which we haven't seen at this point in the day in a very long time.
Resunab Results Keeping Corbus on Fast Track Says CEO
Corbus has surged 325% in 2016 due to Resunab which received an FDA "Fast Track" designation. Corbus CEO Dr. Yuval Cohen does not expect things to slow down anytime soon.
Corbus Ready to Take Cystic Fibrosis Drug the Distance Says CEO
It’s been a hot M&A market for biotech companies developing treatments for rare diseases.
